Skip to content
Download PDF

SARS-CoV-2 and COVID-19

Chapter 205 | Part 5: Infectious Diseases · Part 5 – Infectious Diseases: Viral (incl. HIV) · Chapter 205

Key Clinical Points

  1. SARS-CoV-2 is a Betacoronavirus (Betacoronavirus pandemicum) that emerged in 2019, causing the COVID-19 respiratory disease.
  2. Viral entry is mediated by the S protein binding to hACE2, primed by TMPRSS2.
  3. Key risk factors for severe disease include age (>45 years), high BMI (Overweight ≥25, Obesity ≥30, Severe ≥40), and specific comorbidities like lung disease or immunodeficiency.
  4. Hospitalization criteria: O_2 saturation <94%, respiratory rate >30/min, PaO_2/FiO_2 <300 mmHg, or lung infiltrates >50%.
  5. Nirmatrelvir-ritonavir is the primary outpatient antiviral, administered within 5 days of symptom onset.
  6. Long COVID is defined as a condition persisting for at least 3 months with varied symptoms (fatigue, cognitive deficits).
  7. VTE prophylaxis is recommended for all hospitalized patients.
  8. ACE inhibitors and ARBs should generally be continued in patients with COVID-19.
  9. Antibiotics are not generally indicated unless bacterial superinfection is suspected.
  10. Vaccines have evolved to include bivalent (BA.4/BA.5) and monovalent (XBB, JN.1) formulations.

DEFINITION & CLASSIFICATION

• Definition (Harrison's 20e): SARS-CoV-2 is the cause of a respiratory disease called COVID-19. • Classification: ◦ Member of the Betacoronavirus genus (includes SARS-CoV-1, MERS-CoV, HCoV-OC43, and HCoV-HKU1). ◦ Enveloped, positive-sense RNA viruses. ◦ Genome: ≈ 30,000 nucleotides. • Viral Structure: ◦ Four structural proteins: S (spike), E (envelope), M (membrane), and N (nucleocapsid). ◦ Large polyprotein cleaved into 16 nonstructural proteins. • Entry Mechanism: ◦ Trimeric S protein primed by TMPRSS2 → facilitates entry. ◦ S protein mediates attachment via receptor-binding domain (RBD) binding to human angiotensin-converting enzyme 2 (hACE2).

Historical Context

• WHO Status: ◦ Public Health Emergency of International Concern: January 30, 2020. ◦ Pandemic Declaration: March 11, 2020. ◦ End of Global Emergency: May 5, 2023. • Impact (as of Sept 2024): >700 million cases and >7 million deaths worldwide.

Viral Structure & Replication

• Mutation: RNA-dependent RNA polymerases are error-prone → frequent variants. ◦ Most mutations have no effect or are deleterious. ◦ Specific variations affect transmission, severity, antigenicity, and diagnostic sensitivity. • Monitoring: WHO Technical Advisory Group on SARS-CoV-2 Virus Evolution tracks variant evolution.

EPIDEMIOLOGY

• Origin: Likely existed in a bat reservoir prior to 2019. • Transmission: ◦ First detected in humans: 2019, Wuhan, China. ◦ Rapid human-to-human spread. ◦ Basic reproduction number (R) ≈ 6 (vs. influenza 1–2). • Risk Environments: ◦ High transmission: Prisons, cruise ships, nursing homes, airplanes, large indoor gatherings. ◦ Lower transmission: Outdoor settings. • High-Risk Groups: Healthcare workers, dental workers, and "superspreaders. • School Setting: Not a primary driver of population transmission; children have lower rates of severe disease.

Risk Factors for Severe Illness

• Age: Primary risk factor. ◦ >95% of deaths in patients >45 years. ◦ >80% of deaths in patients >65 years. • Demographics: ◦ Social/health disparities (disability, minority groups) increase risk. ◦ Male sex associated with higher risk (OR ≈ 1.8). • BMI: Risk increases with BMI. ◦ Overweight: BMI >25 but <30. ◦ Obesity: BMI ≥30 but <40. ◦ Severe obesity: BMI ≥40. • Other Factors: Substance use (alcohol, opioid, cocaine), smoking, and pregnancy (increased severity).

Pediatric Considerations

• MIS-C / PMIS: Multisystem inflammatory syndrome in children. ◦ Symptoms: Persistent fever, multi-organ involvement (GI, dermatologic, cardiac, renal, hematologic, neurologic), elevated inflammatory markers. ◦ High-risk group (US): Black and Latino children age 3–12 years. • MIS-A: Similar syndrome in adults (rare).

ETIOLOGY & PATHOPHYSIOLOGY

• Mechanism: Driven by direct viral pathogenesis and associated immune response. • Immune Response: Excessive proinflammatory host response contributes to pulmonary pathology and severity. • Autoimmunity: Manifestations mediated by autoantibodies reported. • Secondary Infections: Bacterial or fungal infections occur (bacteremia, respiratory infections). • Primary Driver: Tissue inflammation and systemic inflammatory responses > direct viral cytopathic effect.

Immune Response & Cytokine Storm

• Systemic Findings: Lymphopenia, thrombocytopenia. ◦ Inflammatory markers: IL-6, TNF-α, ferritin, CRP. ◦ Organ damage markers: Elevated liver enzymes, LDH, D-dimer, prothrombin time, troponin, creatine phosphokinase.

CLINICAL FEATURES

• Timeline: Symptoms typically 4–5 days post-exposure; almost always within 14 days. • Symptoms: Cough, fever, myalgia, headache, dyspnea, sore throat, GI symptoms (nausea, vomiting, diarrhea). • Sensory Loss: Sudden onset of dysgeusia and anosmia (often resolves in weeks/months). • Dermatologic: Diverse findings reported. • Geriatric: Decline of health status or worsening of dementia in older individuals. • Mental Health: Fatigue, depression, anxiety, sleep disturbances, cognitive deficits, PTSD, substance abuse.

Disease Severity Spectrum

• Asymptomatic: ≈1/3 of cases; can still transmit. • Mild: Most symptomatic infections (no pneumonia). • Severe: Requires hospitalization, involves pneumonia, radiographic involvement of >50% lung, or hypoxia (O_2 saturation ≤94%). • Critical: Respiratory failure requiring mechanical ventilation, multiorgan failure, or shock.

Long COVID

• Definition: Chronic condition after SARS-CoV-2 infection present for ≥3 months. ◦ Symptoms: Fatigue, cognitive deficits, cough, dyspnea, chest pain. ◦ Physical: Persistent respiratory or cardiac impairment in those with acute injury. ◦ Mental Health: Altered mental health, decreased brain function, increased suicidal ideation.

DIFFERENTIAL DIAGNOSIS

• Common Respiratory Viruses: Influenza, RSV (most common). ◦ Others: hMPV, PIV3, rhinoviruses. • Immunity: Healthy adults usually develop partial immunity to these pathogens. • High-Risk Groups for Severe Disease: Immunocompromised patients, institutionalized frail elderly, patients with COPD.

Bacterial Superinfection

• Assessment: Evaluate for bacterial complications of respiratory tract viral illness. ◦ Frequency: Bacterial complications are unusual. ◦ Antibiotics: Not generally indicated. ◦ Exception: If diagnosis is uncertain, consider empiric regimens for CAP or HAP.

DIAGNOSTIC APPROACH

  1. Initial Screening: Perform during respiratory symptoms or ≥5 days post-exposure without symptoms.
  2. Sample Collection: Nasopharyngeal swab (most common) or saliva sample.
  3. Test Selection: • Antigen Tests: Detect proteins; used for screening/at-home; less accurate than molecular tests in asymptomatic exposed persons. • Molecular Tests (NAAT/RT-PCR): Detect genetic material; higher sensitivity; performed in professional settings.
  4. Imaging: • Chest Radiograph: May show bilateral consolidation or ground-glass opacities (GGO). Often normal despite respiratory compromise. • Chest CT: Shows GGO, pleural thickening, interlobular septal thickening, air bronchograms. Used for management of respiratory disease, not primary diagnosis. • Lung Ultrasound: Detects B-lines and pleural effusion.

6.1 Diagnostic Criteria & Indications

  1. Hospitalization Decision (NIH Guidelines): ullet Oxygen Saturation <94% on room air → Hospitalize ullet Respiratory Rate >30 breaths/min → Hospitalize ullet PaO_2/FiO_2 <300 mmHg → Hospitalize ullet Lung Infiltrates >50% of lung fields → Hospitalize

MANAGEMENT & TREATMENT

  1. General Principles: ullet Focus on severe respiratory illness and systemic disease. ullet Antibiotics: Not generally indicated unless bacterial infection is suspected. ullet Anticoagulation: Recommended for all hospitalized patients due to VTE risk. ullet Antipyretics: Preferred agent is acetaminophen; avoid NSAIDs if possible (due to potential, though unconfirmed, association with worse outcomes). ullet Chronic Meds: Continue aspirin, statins, ACE inhibitors, or ARBs.
  2. Outpatient Management: ullet Support care for mild disease. ullet Antiviral Selection: Based on risk factors (age ≥65, immunocompromised, multiple comorbidities, or age >50 and unvaccinated). ullet Antiviral Therapy (Nirmatrelvir-ritonavir): → Administer as soon as possible. → Timing: Within 5 days of symptom onset. → Dose: 300 mg + 100 mg orally twice daily for 5 days. → Adjustment: Adjust for renal function; avoid in severe renal dysfunction.
  3. Inpatient Management: ullet Initial assessment: Identify comorbidities, immunocompromise, and organ dysfunction. ullet Fever control: Preferred with acetaminophen. ullet Anticoagulation: Therapeutic dose for all hospitalized patients. ullet Antiviral (Remdesivir): For patients with severe disease and low-flow O_2. → Dose: 3 IV doses over 3 days. ullet Corticosteroids: Dexamethasone or Prednisone for anti-inflammatory treatment. → Monitor for hyperglycemia. ullet Immunomodulators (for escalation): → Criteria: If oxygen requirement escalates in first 4 days + severe disease + high inflammatory markers. → Options: Baricitinib (JAK inhibitor) or Tocilizumab (IL-6 blocker). → Tocilizumab: Humanized mAb against IL-6 receptor; used for patients requiring high-flow O_2, NIV, mechanical ventilation, or ECMO. → Alternatives: Abatacept or Infliximab if first-line not available.

7.3 Antibody-Based Therapies

• Convalescent Plasma: Low effectiveness/reproducibility due to low antibody titers. • Human Monoclonal Antibodies (mAbs): → Used for outpatients with mild-to-moderate infection. → Preliminary data: Vaccinated patients less likely to have Long COVID. • Long-Acting Antibody (LAAB) Combinations: → Tixagevimab + Cilgavimab: FDA expired EUA in 2023 due to escape variants. → Pemivibart: Current EUA for immunocompromised patients unlikely to mount response to vaccine. → Requirement: Only if variant frequency with reduced susceptibility ≤90%. → Dose: 4.5 g IV (for adults/adolescents ≥12 years, weight ≥40 kg).

7.4 Treatment of Complications

• Systemic Effects: Hyperinflammatory and hypercoagulable states lead to ARDS, viral sepsis, cardiac injury, arrhythmias, AKI, and shock. • Antibiotics: No evidence for routine empiric broad-spectrum therapy; deescalate if no bacterial infection evidence. • Specialized Care: Replacement solutions for CRRT, sedation drugs in ICU, and expert consultation for complex anticoagulation.

PROGNOSIS & COMPLICATIONS

• Recovery Time: Influenced by severity, comorbidities, and age. ullet Symptomatic infection: Resolves in ≈2 weeks in 80% of patients (mild/moderate). ullet Severe disease: Requires several months for recovery.